N-{5-[2-Amino-6-(2-benzyloxy-phenyl)-3-cyano-pyridin-4-yl]-2-dimethylamino-phenyl}-3-piperidin-1-yl-propionamide | 643021-69-6

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 吡啶及其衍生物
• 英文名称: N-{5-[2-Amino-6-(2-benzyloxy-phenyl)-3-cyano-pyridin-4-yl]-2-dimethylamino-phenyl}-3-piperidin-1-yl-propionamide
• CAS: 643021-69-6
• 化学式: C₃₅H₃₈N₆O₂
• 分子量: 574.726
• InChiKey: TVEKUAHKXWRVIE-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  6.33
• 重原子数：
  43.0
• 可旋转键数：
  10.0
• 环数：
  5.0
• sp3杂化的碳原子比例：
  0.29
• 拓扑面积：
  107.51
• 氢给体数：
  2.0
• 氢受体数：
  7.0

反应信息

• 作为反应物：
  描述：

  N-{5-[2-Amino-6-(2-benzyloxy-phenyl)-3-cyano-pyridin-4-yl]-2-dimethylamino-phenyl}-3-piperidin-1-yl-propionamide 在 palladium on activated charcoal 氢气 、 溶剂黄146 作用下， 以 乙酸乙酯 为溶剂， 以86%的产率得到N-[5-[2-amino-3-cyano-6-(2-hydroxyphenyl)-4-pyridinyl]-2-(dimethylamino)phenyl]-3-(1-piperidinyl)propanamide
  参考文献：
  名称：

  Discovery of novel and selective IKK-β serine-threonine protein kinase inhibitors. Part 1

  摘要：

  IkappaB kinase beta (IKK-beta) is a serine-threonine protein kinase critically involved in the activation of the transcription factor Nuclear Factor kappa B (NF-kappaB) in response to various inflammatory stimuli. We have identified a small molecule inhibitor of IKK-beta. Optimization of the lead compound resulted in improvements in both in vitro and in vivo potency, and provided IKK-beta inhibitors exhibiting potent activity in an acute cytokine release model (LPS-induced TNFalpha). (C) 2003 Elsevier Science Ltd. All rights reserved.

  DOI：

  10.1016/s0960-894x(02)01046-6
• 作为产物：
  描述：

  4-氯-3-硝基苯甲醛 在 吡啶 、 乙酸铵 、 铁粉 、 氯化铵 作用下， 以 乙醇 、 N,N-二甲基甲酰胺 、 甲苯 为溶剂， 反应 3.0h， 生成 N-{5-[2-Amino-6-(2-benzyloxy-phenyl)-3-cyano-pyridin-4-yl]-2-dimethylamino-phenyl}-3-piperidin-1-yl-propionamide
  参考文献：
  名称：

  Discovery of novel and selective IKK-β serine-threonine protein kinase inhibitors. Part 1

  摘要：

  IkappaB kinase beta (IKK-beta) is a serine-threonine protein kinase critically involved in the activation of the transcription factor Nuclear Factor kappa B (NF-kappaB) in response to various inflammatory stimuli. We have identified a small molecule inhibitor of IKK-beta. Optimization of the lead compound resulted in improvements in both in vitro and in vivo potency, and provided IKK-beta inhibitors exhibiting potent activity in an acute cytokine release model (LPS-induced TNFalpha). (C) 2003 Elsevier Science Ltd. All rights reserved.

  DOI：

  10.1016/s0960-894x(02)01046-6